1315 Capital Invests in Primrose Bio

1315 Capital Backs USpharma Ltd. with Growth Equity Investment

June 30, 2025

Pharmaceuticals

USpharma Ltd., a Miami Lakes-based pharmaceutical development and manufacturing company, received a growth equity investment from Philadelphia-based 1315 Capital. The capital will be used to accelerate development and commercialization of USpharma’s pipeline, expand commercial reach, and scale operations at its 150,000 sq. ft. US-based GMP facility.

1315 Capital and Ampersand Capital Partners Invest $20M in Interpace Biosciences

January 13, 2020

Healthcare Services

Interpace Biosciences entered into an agreement for a $20 million Series B Preferred Stock investment — $19 million from 1315 Capital and $1 million from existing investor Ampersand Capital Partners. The financing (and a coincident one-for-ten reverse stock split) is intended to help Interpace reach cash-flow break-even, accelerate growth and pursue acquisitions; Ampersand also exchanged its Series A preferred for the new Series B shares.

1315 Capital Provides Growth Financing to ProSciento

September 10, 2020

Healthcare Services

ProSciento, a San Diego–based specialty clinical research organization focused on NASH, diabetes and obesity, closed a growth financing round with healthcare investor 1315 Capital. The capital will support expansion of ProSciento's CRO operations and growth of its patient access solutions, including the NASH PASS registry.

Primus Capital Invests in Prendio and BioProcure

October 18, 2023

Cloud & SaaS

Primus Capital has made a growth equity investment in Prendio and sister company BioProcure to support organic growth, expansion into additional life-sciences markets, and continued product and service innovation. The investment will back Prendio's cloud-based eProcurement SaaS and BioProcure's procure-to-pay support services for biotech customers; Aeris Partners served as exclusive financial advisor to the sellers and law firms Latham & Watkins and Goodwin Proctor served as legal advisors.

1315 Capital Invests in Triple Ring Technologies

February 1, 2024

Healthcare Services

1315 Capital, a Philadelphia-based healthcare growth equity firm, made a growth capital investment in Triple Ring Technologies, a Silicon Valley-based medical device and life sciences co-development and engineering services company. The investment will accelerate Triple Ring's geographic expansion and extension of its R&D and product development services to scale its engineering and outsourced R&D services platform.

Primus Capital Leads $40M Series B in PurpleLab

July 27, 2022

Data & Analytics

Primus Capital led a $40 million Series B investment in PurpleLab, Inc., joining existing investor Edison Partners to fund the health‑tech company's growth. The capital will accelerate development of PurpleLab's HealthNexus real‑world data platform, expand data assets, and support hiring and commercial expansion across life‑sciences, payers and providers.